Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of lurasidone on daytime sleepiness in patients with schizophrenia
jRCTs021240065Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma. Primary endpoint: Change from baseline in JESS score after 12 weeks of treatment. Started Jun 2025; status: recruiting.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCTs021240065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021240065.